purpose evaluate feasibility effectiveness concurrent regimen locally advanced carcinomas pharynx floor mouth patients methods january NUMBER NUMBER patients locally advanced carcinomas oro hypopharynx oral cavity uicc stages iii iv treated according accelerated hyperfractionated radiotherapy schedule concurrent chemotherapy primary tumor positive lymph nodes received total dose NUMBER gy NUMBER weeks NUMBER weeks large fields irradiated NUMBER times week NUMBER gy fraction treatment accelerated giving NUMBER daily fractions NUMBER gy minimal intervals NUMBER hours target volumes reduced NUMBER NUMBER gy excluding clinically uninvolved lymph node regions low high risk day NUMBER NUMBER NUMBER folinic acid given intravenous bolus followed continuous infusion NUMBER NUMBER folinic acid days NUMBER NUMBER NUMBER mitomycin c given day NUMBER NUMBER treatment salvage surgery offered residual disease NUMBER NUMBER weeks end radiotherapy patient characteristics NUMBER male NUMBER female age NUMBER NUMBER years NUMBER NUMBER cavity median NUMBER months results overall survival survival NUMBER years results overall survival survival NUMBER years NUMBER NUMBER NUMBER NUMBER multivariate analysis revealed significant influence geometric mean neck node diameter control survival tumor volume tumor localisation did significant acute toxicity schedule acceptable required optimised supportive care treatment related grade NUMBER late toxicity mucosa soft tissue bone observed cumulative frequency NUMBER NUMBER years patients died phase severe thrombocytopenia conclusion phase ii trial shows favourable results using intensified treatment protocol phase iii study planned comparing regime accelerated hyperfractionated increased total dose NUMBER gy radio chemotherapy naso NUMBER fu NUMBER fu follow recurrence free recurrence free n stage loco regional t stage leuko radio chemotherapy radio therapy mg m2 mg m2 mg m2 mg m2 mg m2 t2 t3 t4 n0 n1 n2 n3 nasopharynx oropharynx hypopharynx oral NUMBER NUMBER NUMBER NUMBER